2. Academic Validation
  3. Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay

Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay

  • STAR Protoc. 2024 Oct 5;5(4):103361. doi: 10.1016/j.xpro.2024.103361.
Nancy E Sealover 1,  Jacob M Hughes 1,  Patricia L Theard 1,  Deepan Chatterjee 2,  Amanda J Linke 1,  Bridget A Finniff 1,  Brianna R Daley 1,  Robert E Lewis 2,  Robert L Kortum 3
Affiliations

Affiliations

  • 1 Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
  • 2 Eppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • 3 Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. Electronic address: robert.kortum@usuhs.edu.
PMID: 39369385 DOI: 10.1016/j.xpro.2024.103361
Abstract

Acquired resistance to oncogene-targeted therapies is the major driver of mortality for patients with Cancer. Here, we present a 6-to-16-week assay to model the development of acquired resistance in adherent and suspension Cancer cell lines. We describe steps for determining therapeutic dose, assaying acquired resistance, and testing combination therapies. This protocol is a high-throughput, cost-effective, and scalable method to model acquired drug resistance to established and newly developed therapies. For complete details on the use and execution of this protocol, please refer to Sealover et al.1 and Theard et al.2.

Keywords

Cancer; Cell Biology; Cell culture; Cell-based Assays; High-Throughput Screening.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z